
Almaviva and VoiceBiota Ltd are launching a collaboration through the creation of a joint working group. The strategic partnership will explore new opportunities to bring information related to speech biomarkers to international markets.
VoiceBiota's platform is built on the largest speech biomarker dataset of its kind, which includes 1,800,637 voice recordings from 35 studies conducted in 54 countries. More than 25 international laboratories are currently collaborating to build and expand the dataset. Using artificial intelligence and proprietary methodologies, the platform extracts physiological biomarkers from speech and provides over 46 validated biomarkers related to 16 medical conditions, with an average AUC of 0.899.
The partnership brings together the complementary strengths of Almaviva and VoiceBiota: Almaviva provides digital engineering expertise and experience in the creation of programs, while VoiceBiota provides validated data relating to speech biomarkers.
“Technology creates the greatest value when it listens to people. The voice is one of the most natural and information-rich signals we have, and VoiceBiota has built a solid scientific foundation for interpreting it. Combined with Almaviva's technology and experience in delivering solutions, we see a real opportunity to bring this innovation to the institutions and communities that stand to benefit the most,” said Andrea Leonardo, Director of Almaviva's Healthcare Business Unit.
The partnership will be presented at MedTech World Europe, one of the premier events taking place November 11 to 13, 2026, at the Mediterranean Conference Centre in Valletta, Malta.